Biotech firm Odyssey valued at $899.9 million as shares rises in Nasdaq debut

Odyssey Therapeutics shares rose ​11.1% in its Nasdaq debut on ‌Friday, giving the biopharmaceutical firm a valuation of $899.9 million.